An observational study in BRCA1 and/or BRCA2 Variant Carriers, Ovarian Carcinoma and Fallopian Tube Carcinoma, sponsored by Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan. Recruiting at 1 site in Japan. Open to female participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2026-02-03.
Sponsored by Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 113 studies in Ovarian Neoplasms with a site in Japan — 36 open to participants now, 63 under way, 26 of them phase 3. Ovarian Neoplasms · Japan.
Among the 113 studies in Ovarian Neoplasms with a site in Japan, this one is one of 5 that started in 2017, is one of 7 observational ones, reaches primary completion later than 59 of the 62 other live ones, and was the 42nd registered.
3,390 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.
Browse Ovarian Neoplasms studies →36 of the 113 studies in Ovarian Neoplasms with a site in Japan are open now. Recruiting first, the newest first:
GlaxoSmithKline · Sites in Japan, Argentina, Australia and 2 more countries
Ages 18+ · Women only
AstraZeneca · Sites in Japan, United States, Australia and 10 more countries
Ages 18+ · Women only
GlaxoSmithKline · Sites in Japan, Australia, Canada and 1 more country
Ages 18+ · Women only
Genmab · Sites in Japan, United States, Finland
Ages 18+ · Women only
GlaxoSmithKline · Sites in Japan, Australia, Canada and 2 more countries
Ages 18+ · Women only
A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →
Of the 602 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 108 (18%) stop at 75 or younger; 39 take children under 18; 46 take healthy volunteers.
This study: 20 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
113 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 42 · Phase 2 35 · Phase 3 41
First in 1998; this study’s year is marked. 5 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 600 is above the median of 200 across 617 observational studies indexed under Ovarian Neoplasms.
Median enrollment 399 across the 104 interventional studies, 446 across the 7 observational. Of the 47 that completed or were terminated, 21 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
90 of 113 have an industry lead sponsor. The 10 most frequent:
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan is the lead sponsor of 55 studies on the registry; 2 are open to participants now.
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan has 2 studies filed under Ovarian Neoplasms — fewer than ten, so there is no comparison to draw.
18 of the studies in Ovarian Neoplasms with a site in Japan that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03815643Phase 3EMD Serono Research & Development Institute, Inc.Avelumab Program Rollover Study | 2026-11-24 |
| NCT05059522Phase 3PfizerContinued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing | 2026-12-31 |
| NCT05445778Phase 3AbbVieMirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer | 2027-04 |
| NCT06476184Phase 3ARCAGY/ GINECO GROUPUtility of Adjusting Chemotherapy Dose & Dosing Schedule With the SALVage Weekly Dose-dense Regimen in Patients With Poor Prognostic OVARian Cancers Based on the Tumor Unfavorable Primary Chemosensitivity and Incomplete Debulking Surgery | 2027-06 |
| NCT07214779Phase 3Incyte CorporationStudy to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression | 2027-10-12 |
Add all 18 to your calendar (.ics) → With an account.
Among the 113 studies in Ovarian Neoplasms with a site in Japan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To determine the incidence and risk factors in the development of ovarian, fallopian tube, and peritoneal cancers in Japanese women carrying Breast Cancer Susceptibility Gene (BRCA)1/2 variants.
BRCA1 and/or BRCA2 variant carriers
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Japanese women who carry BRCA 1/2 variants.
Occurrence of ovarian, fallopian tube, and peritoneal carcinoma
Occurrence of ovarian, fallopian tube, and peritoneal carcinoma is a duration from the date of enrollment to the date of first occurrence of ovarian, fallopian tube, and peritoneal carcinoma. If the subjects have undergone RRSO, the duration is defined from the date of enrollment to the date of RRSO conduct
Time frame: up to 15 years
Development of ovarian, fallopian tube, and peritoneal cancers, and the detection rate of occult cancer, based on evaluations of histopathological samples taken post-RSSO.
Development of ovarian, fallopian tube, and peritoneal cancers, and the detection rate of occult cancer is a duration from the date of enrollment to the date of first occurrence of ovarian, fallopian tube, and peritoneal carcinoma. If the subjects have undergone RRSO, the duration is defined from the date of enrollment to the date of RRSO conduct. The occult cancer is defined as ovarian, fallopian tube, peritoneal, and uterine carcinomas (including serious tubal intraepithelial carcinoma, STIC), which is based on evaluations of histopathological samples taken post-RSSO.
Time frame: up to 15 years
Death from any cause
Death from any cause is a duration from the date of enrollment to the date of death from any cause. If the subjects have undergone RRSO, the duration is defined from the date of enrollment to the date of RRSO conduct.
Time frame: up to 15 years
Deaths from ovarian, fallopian tube, and peritoneal cancers.
Deaths from ovarian, fallopian tube, and peritoneal cancers is a duration from the date of enrollment to the date of death from these cancers. If the subjects have undergone RRSO, the term is defined from the date of enrollment to the date of RRSO undergone.
Time frame: up to 15 years
Establishing the detection rate of occult cancer based on histopathological evaluations of samples from RRSO.
The occult cancer is defined as ovarian, fallopian tube, peritoneal, and uterine carcinomas (including serious tubal intraepithelial carcinoma, STIC), which is based on evaluations of histopathological samples taken post-RSSO.
Time frame: up to 15 years
Development of ovarian, fallopian tube, and peritoneal cancers, including in the post-RRSO period.
Development of ovarian, fallopian tube, and peritoneal cancers, including in the post-RRSO period is a duration from the date of enrollment to the date of first occurrence of ovarian, fallopian tube, and peritoneal cancer, including in the post-RRSO period.
Time frame: up to 15 years
Death from any cause, including post-RRSO period.
Death from any cause, including post-RRSO period is a duration from the date of enrollment to the date of death from any cause, including in the post-RRSO period.
Time frame: up to 15 years
Started Nov 2017 (actual). Primary completion is estimated for Mar 2032, 172 months after the start.
Of 216 non-industry observational studies under Ovarian Neoplasms, half reached primary completion within 71 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 206. This study's planned 172 months is above that.
Counting every sponsor, half of 268 studies reached it within 61 months; a quarter within 35 and three quarters within 185.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan